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217 Randomized double-blind monocentric trial on tolerability,
acceptability and efﬁcacy of two formulations of inhaled
7% hypertonic saline with and without hyaluronic acid in
reducing airways inﬂammation in patients with cystic ﬁbrosis −
Preliminary results
A. Brivio1,2, C. Ceruti1,2, S. Gambazza1,2, C. Colombo1,3. 1IRCCS Fondazione Ca`
Granda, Ospedale Maggiore Policlinico Milano, Milan, Italy; 2ARIR: Associazione
Italiana Riabilitatori dell’Insufﬁcienza Respiratoria, Milan, Italy; 3Universita` degli
Studi di Milano, Milan, Italy
Objectives: To evaluate tolerability and efﬁcacy of one month-inhaled 7% hyper-
tonic saline with and without 0.1% sodium hyaluronate in CF patients.
Methods: 26 patients in clinical stable condition have been enrolled in two
groups (7% hypertonic saline vs. 7% hypertonic saline+0.1% sodium hyaluronate −
Hyaneb®). Mean age was 15.7 yrs (range 8−35, sd 6.8) and FEV1 89.5% pred.
(range 46.9–117.4 sd 19.7). All patients have been randomized to two different
treatment groups.
Results: All patients showed a positive response to bronchodilation with short-
acting b2-agonist administered by spacer: FEV1 increased meanly of 5.54% and
MMEF25−75 of 6.2%. A mean increase in FEV1 of 3.2% was reported after four
weeks treatment but difference between two groups was not statistically signiﬁcative
(p = 0.06). FVC did show the same increase of 3.2% without signiﬁcance (p = 0.092).
Total pulmonary resistances decreased of 16.9% (p = 0.46) and RV decreased of
22.55% (p< 0.05). TLC showed a statistically signiﬁcative increased of 4.2%
(p< 0.02). VAS indicated and average degree of satisfaction of 5.73 after the ﬁrst
administration. The adherence questionnaire showed that main reasons for not taking
prescribed aerosol were lack of time in the morning (36%), fatigue in the evening
(28%) and duration of aerosol administration (20%).
Conclusion: Preliminary data show a positive trend in improved mucociliary
clearance and reduced total airways resistances and RV by administration of inhaled
7% hypertonic saline with or without hyaluronic acid. Hypertonic solution shows a
good efﬁcacy in reducing airway obstruction and in increasing pulmonary functions
parameters in the short-term period.
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J. Tame1, K. Ronchetti1, I. Doull1,2, J.T. Forton1,2. 1University Hospital of Wales,
Department of Paediatric Respiratory Medicine, Cardiff, United Kingdom; 2Cardiff
University, Department of Child Health, Cardiff, United Kingdom
Background: CF-SpIT is a paediatric single-centre comparative study of cough
swab, induced sputum, and bronchoscopic lavage for microbiology yield, using both
standard laboratory techniques and culture-independent microbiology. We present
data on tolerability of the induced sputum procedure in the ﬁrst 40 children recruited
to the study.
Methods: Children aged 6 months to 18 years were recruited at annual review
or on hospital admission with chest exacerbation. The induced sputum protocol is
standardised, quick and universally applicable. It was performed in all cases by a
senior respiratory physiotherapist. Questionnaires were completed by physiother-
apist and parent to subjectively assess discomfort from the procedure. Objective
measures including heart rate, respiratory rate, and spirometry in older children,
were recorded pre- and post-procedure.
Results: 38 patients had induced sputum sampling. Of these, 14 were aged 6 years
or less (36%). Secretions were obtained in 25/38 patients (65%). Oropharyngeal
suction was used in 12 patients (31%), mostly in younger children. One patient
did not tolerate the procedure because of vomiting. Transient side effects were
seen in 3 patients (8%). Success in obtaining secretions, subjective assessment of
discomfort, and objective measures of tolerability did not differ between younger
and older children. 37/38 patients and families were willing to have regular induced
sputum sampling in the future, even if secretions had not been successfully obtained
on this occasion.
Conclusion: Induced sputum sampling is well tolerated in children of all ages
including preschool children, and is acceptable to families as part of routine care.
219 Use of the ‘lung ﬂute’ for sputum induction in children with
cystic ﬁbrosis: A pilot study
M. Doumit1. 1Sydney Children’s Hospital, Physiotherapy, Randwick, Australia
Objectives: To assess the effectiveness of the lung ﬂute in obtaining sputum samples
from children with cystic ﬁbrosis (CF) that are not productive of a sample with
coughing alone.
Methods: Children attending an outpatient CF clinic with the ability to expectorate
sputum but not able to provide a sample with vigorous coughing alone were eligible.
Each child was instructed to blow out through the lung ﬂute 2 times followed by
a 5 second rest. These 2 breath cycles were repeated 20 times followed by a 5
minute rest and vigorous coughing. The primary outcome was expectoration of a
sample with at least one macroscopic sputum plug present. Secondary outcomes
were sputum microbiology, time taken to obtain sample, and ease of use of the
device as assessed by the patient using a visual analogue scale (VAS), with 0/10
representing very easy and 10/10 very difﬁcult.
Results: 23 children participated (15 males, mean age 12). 17 children used the
device on one clinic visit and 6 children used the device on 2 visits. A sputum
sample was obtained on 16/29 uses of the device (55%). 15/16 samples yielded
a positive culture result for at least one known CF pathogen. Out of the 16
samples, pseudomonas aeruginosa, staphylococcus aureus, haemophilus inﬂuenzae,
stenotrophomonas maltophili and MRSA were isolated in 6, 11, 3, 1, and 1 sample
respectively. Median time taken to obtain a sample was 10 minutes (range 2−14).
Median ease of use on the VAS was 1/10 (range 0−4).
Conclusion: The lung ﬂute appears to be a clinically useful and easy device
to use for sputum induction in children with CF. Further research comparing its
effectiveness to other sputum induction methods is warranted.
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Objective: Sinonasal pathology can occur in patients with Cystic Fibrosis. This
may cause purulent rhinorrhoea, nasal obstruction, head or ear ache, facial pain
and sleep disturbance as well as general fatigue. These symptoms may adversely
affect quality of life. An audit was conducted to assess the beneﬁt of using DNase
via a sinus nebuliser.
Method: 12 patients (4 male and 8 female, age 20−41 years) who reported sinus
symptoms at annual review, took part in the audit. All the patients who took part
were already using DNase for their lower airways. The rhinosinusitis disability index
(RSDI) was completed together with lung function tests, at the beginning and end
of a month’s treatment. Patients were also asked to comment on any changes to
their quality of life. 7 of the patients reported signiﬁcant improvements to their
symptoms as demonstrated by the questionnaire and were keen to continue with
the treatment. 5 patients did not complete the trial due to no improvement to their
symptoms, being unable to use the nebuliser effectively or being unable to ﬁt the
treatment into their daily routine.
Responders reported marked improvement in facial pain, congestion, taste, appetite,
breathing and sleep patterns. Beneﬁt was also reported on vocal tone, exercise
tolerance, fatigue and concentration.
There was no signiﬁcant improvement to lung function test results in any of the
patients.
Conclusion: DNase administered to the sinuses can provide effective symptomatic
relief in some patients who suffer from sinonasal problems. Further study would
be helpful in identifying which patients may beneﬁt and when intervention should
occur.
